you are here: Home News Pharma

Pharma

As MNCs go missing, domestic firms step up to fill India’s pharma innovation gap
Cipla: Emerging markets to lead growth in the near term
Cipla Q2FY26 preview: Stable quarter seen; domestic growth to cushion US weakness
Dr Reddy’s: Is the weight loss drug the next big opportunity?
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
Laurus Labs: Is the healthy growth already priced in?
Cough syrup deaths: Old regulatory failures resurface as CDSCO calls for ‘strict quality control’
Govt invites proposals under PRIP scheme for industry, startup projects
Select pharma shares fall between 4-7% as Trump's tariffs on branded drugs sour sentiment
InvAscent-backed Malladi Drugs planning Rs 1,200-crore IPO, holds talks with banks
Moneycontrol Pro Panorama | A Rs 1000-crore Rx heavyweight in the making
Relief for pharma sector as govt waives mandatory re-labelling of medicines after GST rate cut
GST rate cuts to benefit players across the healthcare sector
Trump doubles tariff from Aug 27: Indian labour-intensive goods face over 50%, pharma, tech remain spared
India's pharma, chemical tariffs lower compared to China
Sun Pharma: Innovative drugs are near-term growth drivers
How Novo Nordisk lost its lead in the weight loss race
Laurus Labs: Is it time to book profit?
Cipla: Non-US markets to drive growth in the near term
Cipla Q1FY26 preview: Margin pressure likely despite double-digit India growth
Dr Reddy’s Q1FY26 preview: US headwinds may weigh on margins but revenue may see double-digit growth
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
Cohance Lifesciences Q1 PAT may dip 64.2% YoY to Rs 51.6 cr: ICICI Securities
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Pharma

As MNCs go missing, domestic firms step up to fill India’s pharma innovation gap

Cipla: Emerging markets to lead growth in the near term

Cipla Q2FY26 preview: Stable quarter seen; domestic growth to cushion US weakness

Dr Reddy’s: Is the weight loss drug the next big opportunity?

Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates

Laurus Labs: Is the healthy growth already priced in?

Cough syrup deaths: Old regulatory failures resurface as CDSCO calls for ‘strict quality control’

Govt invites proposals under PRIP scheme for industry, startup projects

Select pharma shares fall between 4-7% as Trump's tariffs on branded drugs sour sentiment

InvAscent-backed Malladi Drugs planning Rs 1,200-crore IPO, holds talks with banks

Moneycontrol Pro Panorama | A Rs 1000-crore Rx heavyweight in the making

Relief for pharma sector as govt waives mandatory re-labelling of medicines after GST rate cut

GST rate cuts to benefit players across the healthcare sector

Trump doubles tariff from Aug 27: Indian labour-intensive goods face over 50%, pharma, tech remain spared

India's pharma, chemical tariffs lower compared to China

Sun Pharma: Innovative drugs are near-term growth drivers

How Novo Nordisk lost its lead in the weight loss race

Laurus Labs: Is it time to book profit?

Cipla: Non-US markets to drive growth in the near term

Cipla Q1FY26 preview: Margin pressure likely despite double-digit India growth

Dr Reddy’s Q1FY26 preview: US headwinds may weigh on margins but revenue may see double-digit growth

Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities

Cohance Lifesciences Q1 PAT may dip 64.2% YoY to Rs 51.6 cr: ICICI Securities

Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities

Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities